The review is aimed at presenting the advances in the field of probiotics based on information gleaned from the patents filed internationally in last 15 years. The review explains the concept of probiotics and discusses the established microbes like lactobacilli and bifidobacteria and some emerging new candidates. The global market trend for probiotics is presented with related aspect of business, how patents can be leveraged as business tool to create monopoly and secure future business. Patents related to GIT are discussed at length. The scope has expanded considerably now and patents related to important findings as judged from claims from such patents are explained in depth. Further, more patents that are studied pertain to novel applications related to fat metabolism, obesity, weight management, oral health, anticancer treatments, cardiovascular disorders, diabetes, etc. Few other patents foraying in to the area of immunomodulation, allergies and antioxidant activity are taken into consideration. Other patents are also included that address the challenges related to dreadful viral diseases including AIDS and rare but serious inborn errors of metabolism. The review also enlists salient features of patents dealing with therapeutic effects with existing gut probiotics but with increased viability, use of unconventional bacterial probiotic strains capable of surviving in hostile gut conditions, innovative compositions to increase acceptability and novel methods to deliver the same. New research pertaining to probiotics having role in cosmetics & skin care and veterinary applications is also taken into account. The review is concluded by throwing some light on the trend in the ongoing research as well as some speculation on the future trend. It can be envisaged that the rapid advances in the field certainly hold a huge promise to mankind as it has tremendous scope to deliver a plethora of health advantages.
There is a growing demand today for naturally derived drugs and medicine in place of synthetic drugs that are more commercially available. Such drugs derived from indigenous plants are effective as they contain potent therapeutically active compounds of the plants that show antimicrobial activity against a variety of pathogens that cause common diseases. Such diseases as periodontitis and oral candidiasis are a growing concern these days. This study was undertaken to investigate the antimicrobial activity of two indigenous Indian plants, Azadirachta indica and Murraya koenigii and their synergistic effect, if any, against three pathogenic microorganisms associated with oral diseases and one pathogenic bacteria known to be a nosocomial causative agent. Three bacterial species (Streptococcus mutans, Streptococcus gordonii, Pseudomonas aeruginosa) and one fungal species (Candida albicans) were selected for antimicrobial assays. Both ethanolic and methanolic extracts were prepared from the leaves of the two plant species in addition to an aqueous extract of A. indica and an n-hexane extract of M. koenigii. Antibacterial and antifungal assay was done using agar well diffusion method under standard culture conditions. Inhibitory activity was observed for all extracts against P. aeruginosa while A. indica and M. koenigii showed ineffectiveness in inhibiting growth of C. albicans and S. mutans respectively. C. albicans and S. mutans were selected for study of synergistic effect based on the results of the initial assay, however there was no synergistic activity observed for any combination of extract mixtures.
Polyhydroxyalkanoates (PHA) are synthesized by bacteria under unfavourable growth conditions like excess of carbon over nitrogen, coupled with oxygen limitation. The PHA polymers of microbial origin are diverse in chemical composition and material properties. A bioprocess for PHA production by indigenously isolated Bacillus flexus MTCC 12841 was devised and optimized at a laboratory fermentor scale. Fermentation strategies that involved modifications in some parameters like aeration, agitation, temperature, nutrient feeding or changes in C:N ratio led to substantial improvement of 59% in PHA production reaching highest concentration of 9.73 g/L. Biomass too was enhanced to 15.70 g/L equivalent to 126% increase over the optimized shake flask runs. PHA (Yp/s) and biomass (Yx/s) yields were found to be 0.32 and 0.51 g/g respectively, indicating good carbon utilization efficiency. The characterization of polymer by GC-MS revealed that the culture produced poly-3-hydroxybutyrateco-3-hydroxyvalerate (PHBV) as a co-polymer. The novelty of the research findings lies in the demonstration of increased production of PHA at lab fermentor level coupled with the identification of the natural ability of the strain to also produce PHBV without any need for exogenous addition of precursors. The fermentation process as well as the strain may be subjected to further optimization to increase the PHA production as well as to increase the % of HV content in the co-polymer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.